

## Addyi® (flibanserin) Prescribing Checklist

Prior to prescribing Addyi (flibanserin) the health care professional should consider using the Prescribing Checklist as a tool to confirm the patient's eligibility for treatment. If the patient is found to be eligible, an informed consent is to be obtained from the patient in accordance with provincial/territorial legislation and any standards/guidelines.



### About Addyi:

Addyi is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire for a minimum of 6 months, which occurs 75-100% of the time, causes marked distress or interpersonal difficulty and is NOT due to:

- A co-existing medical or psychiatric condition,
- Problems within the relationship, or
- The effects of a medication or other drug substance.

### Addyi should not be prescribed to any patients with a NO response for questions 1-5

1. In the past, was the patient's level of sexual desire or interest good and satisfying to them?  Yes  No
2. Has there been a decrease in the patient's level of sexual desire or interest?  Yes  No
3. Has sexual desire been decreased for over 6 months, 75-100% of the time?  Yes  No
4. Is the patient bothered by their decreased level of sexual desire or interest?  Yes  No
5. Would the patient like their level of sexual desire or interest to increase?  Yes  No

### Clinical judgment should be used if prescribing Addyi to patients with a YES response to any of the questions below, as a primary diagnosis other than HSDD may be present.

1. Are there any factors that may be contributing to their current decrease in sexual desire or interest?
  - A. An operation, depression, injuries, or other medical condition  Yes  No
  - B. Medications (ex. SSRIs), drugs, or level of alcohol they are currently taking  Yes  No
  - C. Recent childbirth, menopausal symptoms  Yes  No
  - D. Other sexual issues they may be having (pain, decreased arousal or orgasm)  Yes  No
  - E. Their partner's sexual problems  Yes  No
  - F. Dissatisfaction with their relationship or partner  Yes  No
  - G. Stress or fatigue  Yes  No

### Contraindications for prescribing Addyi

Addyi should not be prescribed to any patients with a YES response to the questions below.

1. Does the patient have hepatic impairment?  Yes  No
2. Is patient pregnant or breastfeeding?  Yes  No
3. Is patient currently using alcohol and has a resting systolic blood pressure <110 mmHg or diastolic blood pressure <60 mmHg?  Yes  No
4. Is patient taking any moderate or strong CYP3A4 inhibitors?  
Some examples of moderate or strong CYP3A4 inhibitors include:  
ritonavir, flucanazole, ciprofloxacin, erythromycin, boceprevir, nefazodone  
and grapefruit juice.  Yes  No  
Please consult the Addyi Product Monograph for additional guidance.
5. Does patient have hypersensitivity to flibanserin or other components  
of Addyi?  Yes  No

### Patient counseling for safe use of Addyi

Patients should be counseled on how to take Addyi to promote safe use of the medication

1. Addyi is dosed at bedtime because administration during waking hours increases the risks of hypotension, syncope, and CNS depression (such as somnolence and sedation).  Completed
2. The importance of limiting their alcohol intake in combination with Addyi, as the combination of Addyi and alcohol may increase the risk of severe low blood pressure.  Completed
3. The patient should be discouraged from driving, operating machinery or engaging in activities that require clear thinking until 6 hours after taking Addyi and until they know how it may affect them.  Completed
4. If patient misses a dose, they should be instructed to skip that dose and take their next dose at bedtime of the following day. Increased doses are not associated with greater effect and can increase the risks of side effects.  Completed
5. Addyi must be used with caution in patients with any pre-existing cardiovascular conditions. Side effects from Addyi use have included tachycardia, palpitations, hypotension and syncope.  Completed
6. Patient should be cautioned that not all women benefit from treatment with Addyi. Treatment should be discontinued after 8 weeks if there has been no improvement.  Completed
7. Patient gives consent to treatment with Addyi.  Consent
8. Patient has been given a copy of the "Patient Handout".  Completed

**For additional information please consult the Addyi Product Monograph.**